Author

H. Crawford

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:cancer & tumor microenvironment· 4 Research Focus:drug response / drug discovery· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2

Frequent Co-Authors

J. Shi· 2 shared M. Pasca di Magliano· 2 shared Y. Zhang· 2 shared A. Ashworth· 1 shared A. Bischoff· 1 shared A. Brannon· 1 shared A. Goodrum· 1 shared A. Gulati· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Shi

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Arginase 1 is a key driver of immune suppression in pancreatic cancer

R. E. Menjivar, Z. C. Nwosu, W. Du, K. Donahue, C. Espinoza, K. Brown, A. Velez, W. Yan, F. Lima, A. Bischoff, P. Kadiyala, D. Salas-Escabillas, C. J. Halbrook, F. Bednar, E. Carpenter, , M. di Magliano

This study shows that Arginase 1 suppresses immune responses in pancreatic cancer by inhibiting T cell activation, and targeting it enhances immunotherapy effectiveness.

bioRxiv · Jun 21, 2022Cancer Biology

KMT2D Links TGF-β Signalling to Non-Canonical Activin Pathway and Regulates Pancreatic Cancer Cell Plasticity

S. Lu, H. S. Kim, Y. Cao, K. Bedi, K. Chain, L. Zhao, I. V. Narayanan, Z. Yi, J. Yang, Y. Gu, M. T. Paulsen, M. Ljungman, S. Jeyarajan, D. Thomas, Y. Dou, , J. Shi

This study identifies KMT2D as a tumor suppressor in pancreatic cancer, linking TGF-β signaling to the non-canonical activin A pathway through miR-147b and showing its role in cancer cell plasticity and metastasis.

bioRxiv · Apr 2, 2020Cancer Biology

Beta 1 Integrin Signaling Mediates Pancreatic Ductal Adenocarcinoma Resistance to MEK Inhibition

A. Brannon, D. Drouillard, N. Steele, S. Sutherland, H. Crawford, M. Pasca di Magliano

This study identifies integrin β1 signaling as a mediator of MEK inhibitor resistance in pancreatic cancer organoids, suggesting combination therapy targeting both pathways.

bioRxiv · Jan 6, 2020Cancer Biology

An Essential Role for Argonaute 2 in EGFR-KRAS Signaling in Pancreatic Cancer Development

S. Shankar, J. Tien, R. F. Siebenaler, S. Chugh, V. L. Dommeti, S. Zelenka-Wang, J. Waninger, K. M. Juckette, A. Xu, X.-M. Wang, M. Mody, S. Eyunni, A. Goodrum, G. Tsaloff, Y. Zhang, , A. M. Chinnaiyan

This study shows AGO2 is required for pancreatic cancer progression but not initiation, with its role dependent on mutant KRAS and EGFR signaling.

bioRxiv · Aug 1, 2019Cancer Biology

Targeting DNA damage response and Replication Stress in Pancreatic Cancer

S. Dreyer, R. Upstill-Goddard, V. Paulus-Hock, C. Paris, E. Maria-Lampraki, E. Dray, B. Serrels, S. Rebus, H. Brunton, C. Nourse, U.-M. Bailey, M. Jones, K. Moran-Jones, D. Wright, F. Duthie, , Lord

The paper identifies novel therapeutic strategies for pancreatic cancer by analyzing DNA damage response and replication stress in patient-derived cell lines.

bioRxiv · Jul 24, 2019Cancer Biology